ZAVESCA® Clinical Trials

Study Design

ZAVESCA® has been studied in approximately 80 patients with type 1 Gaucher disease across three clinical trials.

The majority of patients were in the clinical trial for 6-12 months.

The studies looked at changes in the sizes of the liver and spleen as well as the concentration of hemoglobin (a protein in red blood cells that carries oxygen) and number of platelets.

Study Findings

In clinical studies, patients with mild to moderate type 1 Gaucher disease taking ZAVESCA® achieved*:

Reduced swelling of
liver and spleen

Increased levels of
hemoglobin

Increased levels of
platelets

*The results shown above varied among patients and clinical trials. Overall, patients taking ZAVESCA® had decreases in liver and spleen volume. Changes in hemoglobin levels and platelet counts (both increases and decreases) were seen across the studies.

What are the possible side effects of ZAVESCA®?

ZAVESCA® may cause serious side effects including:

The most common side effects of ZAVESCA® are:

  • Weight loss
  • Stomach pain
  • Gas
  • Nausea and vomiting
  • Headache, including migraine
  • Back pain
  • Constipation
  • Dry mouth
  • Heaviness in arms and legs
  • Memory loss
  • Unsteady walking
  • Loss of appetite
  • Leg cramps
  • Dizziness
  • Weakness
  • Vision problems
  • Muscle cramps
  • Indigestion
  • Numbness, tingling, pain, or burning of your skin
  • Stomach bloating
  • Stomach pain not related to food
  • Menstrual changes

Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of ZAVESCA®. For more information, ask your doctor or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see full Prescribing Information and Patient Information.

Reference:

ZAVESCA® (miglustat) full Prescribing Information. Actelion Pharmaceuticals US, Inc.

Expand ISI +